Earnings summaries and quarterly performance for Natera.
Executive leadership at Natera.
Steven Chapman
Detailed
Chief Executive Officer and President
CEO
DR
Daniel Rabinowitz
Detailed
Chief Legal Officer and Secretary
JF
John Fesko
Detailed
President, Chief Business Officer
MR
Matthew Rabinowitz
Detailed
Executive Chairman
MB
Michael Brophy
Detailed
Chief Financial Officer
SM
Solomon Moshkevich
Detailed
President, Clinical Diagnostics
Board of directors at Natera.
Research analysts who have asked questions during Natera earnings calls.
Daniel Brennan
TD Cowen
5 questions for NTRA
Also covers: A, ADPT, AVTR +24 more
PS
Puneet Souda
Leerink Partners
5 questions for NTRA
Also covers: A, ABCL, BRKR +20 more
Catherine Schulte
Baird
4 questions for NTRA
Also covers: A, CSTL, EXAS +7 more
Tycho Peterson
Jefferies
4 questions for NTRA
Also covers: A, AVTR, BIO +22 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for NTRA
Also covers: A, ADPT, AKYA +14 more
TS
Tejas Savant
Morgan Stanley
3 questions for NTRA
Also covers: ADPT, AKYA, AVTR +19 more
Douglas Schenkel
Wolfe Research, LLC
2 questions for NTRA
Also covers: A, AVTR, BRKR +21 more
Doug Schenkel
Wolfe Research LLC
2 questions for NTRA
Also covers: A, AVTR, BRKR +15 more
CW
Casey Woodring
JPMorgan Chase & Co.
1 question for NTRA
Also covers: A, BLLN, CRL +11 more
CB
Colleen Babington
Wolfe Research, LLC
1 question for NTRA
Also covers: CARS, GRAL, TEM +1 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for NTRA
Also covers: A, AVTR, BIO +15 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
1 question for NTRA
Also covers: A, ADPT, AVTR +21 more
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for NTRA
Also covers: CRL, CTKB, MRVI +4 more
Noah
Jefferies
1 question for NTRA
Also covers: VFC
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for NTRA
Also covers: A, AKYA, AVTR +11 more
Subbu Nambi
Guggenheim Securities
1 question for NTRA
Also covers: BOLD, BRKR, CARS +16 more
SN
Subhalaxmi Nambi
Guggenheim Securities
1 question for NTRA
Also covers: AKYA, BRKR, CSTL +15 more
Recent press releases and 8-K filings for NTRA.
Natera Submits Signatera CDx PMA to FDA
NTRA
- Natera has submitted its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signatera™ CDx.
- The submission is for the detection of molecular residual disease (MRD) in patients with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with atezolizumab (Tecentriq®).
- This application is supported by data from the randomized, double-blind, phase 3 IMvigor011 clinical trial, which met its primary endpoint and demonstrated significant improvements in disease-free survival and overall survival for Signatera-positive patients treated with atezolizumab.
- If approved, Signatera CDx has the potential to be the first companion diagnostic MRD test to guide treatment decisions and improve outcomes for MIBC patients.
2 days ago
Natera Completes Enrollment in Pivotal Heart Transplant Trial
NTRA
New Projects/Investments
Product Launch
- Natera, Inc. (NTRA) has completed enrollment in its ACES-EMB trial, a randomized-controlled study evaluating the Prospera Heart test for rejection monitoring in heart transplant recipients.
- This trial is the first randomized-controlled study to compare non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance with routine invasive biopsies in organ transplantation.
- Positive results could lead to a fundamental shift in the standard of care, replacing invasive biopsies with the non-invasive Prospera test for approximately 4,500 heart transplants annually in the United States.
7 days ago
Natera Reports Strong Q4 2025 Performance, New Product Launches, and Strategic Investments
NTRA
Revenue Acceleration/Inflection
Product Launch
M&A
- Natera reported robust Q4 2025 results, with revenues increasing 39% over Q4 2024 to $660 million and Signatera achieving its fastest growth quarter ever with 22,000 clinical MRD tests. The company also generated over $100 million in free cash flow throughout 2025.
- The company launched new products including the Fetal Focus 21-gene NIPT test and the Latitude tumor-naive MRD product. Natera also acquired Foresight Diagnostics to integrate phased variants technology into Signatera for enhanced sensitivity, with a new version launching in late spring/early summer 2026, expanding into lymphoma and hematologic cancers.
- Natera is investing an additional $100 million in breast cancer clinical trial evidence development and partnered with Exelixis for the STELLAR Phase 3 trial in colorectal cancer, leveraging its commercial MRD patient base. The company aims to complete enrollment for the FDA-enabling FIND study for early cancer detection in 2026, targeting FDA submission by mid-2027.
- Natera announced an AI-based foundation model for augmented MRD scoring, expected to roll out mid-2026, and is pursuing expanded Medicare coverage through seven additional Multi-X submissions. The company anticipates 10% year-on-year OPEX growth in 2026, primarily in R&D, as it grows towards profitability.
Jan 14, 2026, 12:30 AM
Natera Reports Strong Q4 2025 Results and Outlines Key 2026 Growth Initiatives
NTRA
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Natera achieved a record year in 2025 across women's health, organ health, and oncology, with Q4 2025 revenue up 39% over Q4 2024 to $660 million and over $100 million in free cash flow generated throughout 2025.
- The company reported a record 924,000 units in Q4 2025, driven by strong growth in Signatera MRD, which saw 22,800 growth units over the previous quarter, totaling 22,000 clinical MRD tests in the quarter.
- Natera plans to roll out an AI-enhanced MRD score mid-year 2026 and launch Signatera genome with phased and structural variants in mid-2026, expanding its oncology offerings.
- For early cancer detection, Natera aims to complete enrollment for the FDA-enabling FIND study in 2026 with over 35,000 patients, targeting an FDA submission in mid-2027.
- The company projects 10% year-on-year OPEX growth in 2026, primarily in R&D, and expects continued growth in Signatera Average Selling Prices (ASPs) driven by expanded Medicare reimbursement and biomarker state laws.
Jan 14, 2026, 12:30 AM
Natera reports strong preliminary Q4 2025 financial results and announces new product developments
NTRA
Earnings
Product Launch
M&A
- Natera reported preliminary total revenues of $660 million for Q4 2025, an increase of 39% over Q4 2024.
- The company achieved record volumes in Q4 2025 with 924K tests processed and record clinical MRD volumes of 225K tests in the same quarter.
- Natera launched the 21-gene Fetal Focus single-gene NIPT and Signatera designed on Genome in mid-2025, and acquired Foresight Diagnostics.
- Key anticipated milestones for 2026 include expanded MolDX coverage, the launch of Signatera in Japan, and collaborations in AI and sequencing.
Jan 14, 2026, 12:30 AM
Natera Reports Strong 2025 Performance and Outlines 2026 Growth Initiatives
NTRA
Revenue Acceleration/Inflection
New Projects/Investments
M&A
- Natera reported a record year in 2025 across women's health, organ health, and oncology, with Q4 2025 revenue of $660 million, up 39% over the similar period in 2024, and over $100 million in free cash flow generated for the year.
- The company saw its fastest growth quarter ever for Signatera MRD, with 225,000 clinical MRD tests in Q4 2025, representing 22,800 growth units over the previous quarter.
- Natera is expanding its oncology offerings by integrating Foresight Diagnostics' phased variants technology into Signatera for a new version launching in late spring/early summer 2026, aiming for ultra-high sensitivity, and moving into the lymphoma and hematologic cancer space.
- Key 2026 milestones include launching the enhanced Signatera, completing enrollment for the FDA-enabling FIND study in early cancer detection with a target of 35,000+ patients for submission in mid-2027, and expecting continued growth in average selling prices (ASPs) and volume.
- The company anticipates 10% year-on-year OpEx growth in 2026, primarily in R&D, and expects to grow into profitability, with Signatera ASPs projected to improve in 2026 due to expanded Medicare reimbursement and biomarker laws.
Jan 14, 2026, 12:30 AM
Natera Reports Strong Test Volume and Revenue Growth in Expanding Genomic Testing Market
NTRA
Revenue Acceleration/Inflection
New Projects/Investments
- The global genomic testing market is projected to reach a valuation of USD 41.34 billion by 2035, growing at a CAGR of 9.54% from USD 16.62 billion in 2025.
- Natera processed approximately 3.5 million total tests in the full year 2025, marking a 15% increase over 2024, with oncology-specific volumes reaching 800,800 tests in 2025, a 52% year-over-year increase.
- Financially, Natera's Q4 2024 revenue grew by 53% year-over-year, and the company achieved a 63% gross margin in Q4 2024, reporting cash inflows greater than USD 100 million for the full year 2025.
- The market is significantly driven by reagents and consumables, which account for over 46.7% of the market share, and sequencing solutions, holding a 66.73% market share.
Jan 13, 2026, 2:30 PM
Natera Announces Breakthrough in MRD-Based Risk Stratification with New AI Model
NTRA
Product Launch
New Projects/Investments
- Natera announced a breakthrough in MRD-based risk stratification with a new multi-modal AI model designed to enhance its Signatera™ assessment.
- This AI model integrates longitudinal ctDNA, clinical data, digital pathology, and tumor sequencing data to refine recurrence risk assessment and outcomes prediction.
- Trained on Natera's proprietary database of approximately 300,000 patients, the approach has demonstrated statistically and clinically significant enhancements.
- Data from this innovation is expected to be presented at an upcoming conference, with launches anticipated in research and clinical settings.
Jan 13, 2026, 1:00 PM
Natera Announces Preliminary Q4 and Full Year 2025 Financial Results
NTRA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Natera, Inc. reported preliminary unaudited total revenues of approximately $660 million for Q4 2025, a 39% increase from Q4 2024, and approximately $2.3 billion for the full year 2025, a 35% increase from FY 2024.
- The company processed approximately 923,600 tests in Q4 2025, up 17% from Q4 2024, and 3,525,500 tests for the full year 2025, up 15% from FY 2024.
- Oncology tests, including clinical molecular residual disease (MRD) tests, showed significant growth, with approximately 233,300 oncology tests processed in Q4 2025 (up 55% from Q4 2024) and 800,800 for the full year 2025 (up 52% from FY 2024).
- Natera achieved cash inflows of approximately $30 million in Q4 2025 and greater than $100 million for the full year 2025.
| Metric | Q4 2024 | Q4 2025 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Total Revenues ($USD Millions) | $476 | $660 | $1,700 | $2,300 |
| Total Tests Processed (Units) | 792,800 | 923,600 | 3,064,600 | 3,525,500 |
| Oncology Tests Processed (Units) | 150,800 | 233,300 | 528,200 | 800,800 |
| Clinical MRD Tests Processed (Units) | 144,500 | 225,300 | 498,300 | 769,700 |
| Cash Inflows ($USD Millions) | $46 | $30 | N/A | >$100 |
Jan 12, 2026, 9:03 PM
Natera Collaborates with NVIDIA to Scale AI Foundation Models
NTRA
New Projects/Investments
Product Launch
- Natera announced a new collaboration with NVIDIA to accelerate the development of its multimodal AI foundation model platform for precision medicine.
- This partnership aims to establish the computational infrastructure required to train and deploy large-scale AI models on complex medical datasets, enabling more precise diagnostics, deeper biological insight, and personalized therapeutic decisions.
- Natera's AI solutions are anchored by one of the world's largest multimodal, longitudinal oncology datasets, with algorithms like NeoSelect™ and NeoPredict™ demonstrating strong performance in neoantigen and immunotherapy response prediction.
- The integration of NVIDIA's platforms, including Parabricks, BioNeMo, and NeMo Agent Toolkit, has shown significant efficiency gains, such as an average 75.7% reduction in running time and 59.2% reduction in cost for genomic analysis.
Jan 12, 2026, 3:00 PM
Quarterly earnings call transcripts for Natera.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more